Skip to main content
Log in

Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?

  • Letter to the Editor
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

    Article  PubMed  CAS  Google Scholar 

  2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    Article  PubMed  Google Scholar 

  3. Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:8–13.

    Article  PubMed  Google Scholar 

  4. Chayama K, Hayes CN, Ohishi W, Kawakami Y. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.

    Article  PubMed  CAS  Google Scholar 

  5. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.

    Article  PubMed  CAS  Google Scholar 

  6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Dr. N. Kawada has received grants from MSD K.K. and Chugai Pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Norifumi Kawada.

Additional information

An answer to this letter to the editor is available at doi:10.1007/s00535-013-0760-y.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enomoto, M., Tamori, A., Kobayashi, S. et al. Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?. J Gastroenterol 48, 555–556 (2013). https://doi.org/10.1007/s00535-013-0759-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-013-0759-4

Keywords

Navigation